IASO Biotherapeutics (IASO Bio), a Chinese cell therapy innovator, announced that the Investigational New Drug (IND) application for its in vivo CAR‑T product IASO208 has been approved by China’s National Medical Products Administration (NMPA). The clearance follows implicit IND approval from the US Food and Drug Administration (FDA) in September 2026, positioning IASO208 for parallel clinical development in both major markets.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agencies | NMPA (China) – IND approved 11 Nov 2026; FDA (US) – implicit IND approval, September 2026 |
| Product | IASO208 – CD20‑targeting in vivo CAR‑T therapy |
| Platform | IASO Bio’s proprietary InTelliCAR™ platform |
| Distinction | First lentiviral vector‑based in vivo CAR‑T product in China to receive FDA IND clearance |
| Intended Indication | Adult patients with relapsed or refractory B‑cell non‑Hodgkin lymphoma (R/R B‑NHL) |
| Next Steps | Direct entry into a Phase Ib clinical study in the United States, supported by Chinese investigator‑initiated trial (IIT) data |
Drug Profile & Mechanism of Action
- Modality: In vivo CAR‑T — a next‑generation approach in which the CAR construct is delivered directly inside the patient, genetically engineering T cells in situ rather than manufacturing them ex vivo from harvested cells.
- Target: CD20, a surface antigen broadly expressed on malignant B cells, making it an established target in B‑cell lymphoma therapy.
- Vector: Lentiviral vector‑based delivery — the first product of its kind developed in China to win FDA IND clearance, underscoring the regulatory acceptance of this in vivo engineering approach.
- Platform: Built on IASO Bio’s proprietary InTelliCAR™ platform, the company’s in vivo CAR‑T technology engine.
- Potential Advantage: By bypassing ex vivo cell manufacturing, in vivo CAR‑T aims to deliver an “off‑the‑shelf” cell therapy experience — addressing the cost, vein‑to‑vein time and scalability constraints that have limited conventional CAR‑T access.
Clinical Development – IIT to Phase Ib
- Supporting Data: The program will proceed directly to Phase Ib in the United States based on data from investigator‑initiated trials (IIT) in China — evidence sufficient for regulators to permit skipping earlier dose‑finding stages.
- IIT Data Details: Specific response rates, safety figures and patient numbers – not disclosed in the announcement.
- Study Population: Adults with R/R B‑NHL, a population with high unmet need whose disease has relapsed after or is refractory to standard immunochemotherapy.
- Trial Scope: US Phase Ib site count, enrollment targets and timelines – not disclosed.
Market Impact & Outlook
- In Vivo CAR‑T Race: The field is emerging as one of the most closely watched frontiers in cell therapy, with global players pursuing in vivo engineering to transform CAR‑T from a bespoke, resource‑intensive procedure into a scalable injectable product.
- Dual‑Market Strategy: Back‑to‑back FDA (September 2026) and NMPA (November 2026) IND clearances give IASO Bio a synchronized China‑US development path — a strategically valuable footprint for a Chinese cell therapy innovator.
- First‑Mover Signal: As the first lentiviral vector‑based in vivo CAR‑T from China to receive FDA IND clearance, IASO208 carries milestone significance for the credibility of domestic in vivo cell therapy platforms on the global stage.
- Commercial Outlook: Early‑stage; value will depend on Phase Ib safety and efficacy readouts. Partnership, financing and licensing terms – not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical trial initiation and outcomes, and development plans for IASO208. Actual results may differ materially due to risks including clinical safety and efficacy findings, enrollment progress, subsequent regulatory requirements in the US and China, and competitive dynamics in the CAR‑T field. No efficacy data or commercial projections have been disclosed by the company.-Fineline Info & Tech
